profit from every $100 of sales.
$0$100
CDT Equity
$0.40-9.66% today
-100.0% in 1 year
1-year low $0.401-year high $14,437.50
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What CDT Equity sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$39.2 million of profit last year.
SalesProfit
CDT Equity vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| CDT Equity | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads CDT Equity's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -3 | -5 | -15 | -37 | |
| -5 | 3 | -16 | -36 | |
| -5 | -1 | -18 | -39 | |
| -20,278.01 | -24,617.89 | -38,616.05 | -1,177.89 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 7 | 4 | 6 |
| Cash | 0 | 4 | 1 | 2 |
| Total debt | 2 | 1 | 7 | 1 |
| Total liabilities | 10 | 8 | 11 | 13 |
| -10 | -0 | -7 | -7 | |
| 0 | 0 | 0 | 0 | |
| – | 456.8% | -1,938.8% | – | |
| 48.4% | 117.1% | 262.1% | 547.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2 | -8 | -10 | -16 | |
| – | – | 0 | 2 | |
| -2 | -8 | -10 | -18 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 0 | |
| 0 | 0 | 2 | 2 |
Valuation
- –
- –
- –
- -0.1×
- –
- –
- 13.5×
- -4,406.3%
- -9,624.3%
- 0.0%
Profitability
- 36.9%
- 6.4%
- 2.4%
- 11.5%
- 0.9%
- -759.8%
- 2.6%
- 0.5%
- 1.6%
- 4.9%
Growth
- –
- –
- −84.5%
- –
- +417.7%
Financial health
- 0.0×
- -0.11
- 39.0%
- -122.0×
- 0.34
- 1.40
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 39%of 946
Bottom 44%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.31 | – | – |
| Apr 3, 2026 | -99.99 | – | – |
| Nov 13, 2025 | -13.16 | – | – |
| Aug 14, 2025 | -43.68 | – | – |
| May 15, 2025 | -158.32 | – | – |
| Mar 28, 2025 | -2,438.38 | – | – |
| Nov 14, 2024 | -839.58 | – | – |
| Aug 12, 2024 | -839.58 | – | – |
News
Update: Sliding Chipmakers Push US Equity Indexes Lower While Producer Prices Growth Below ForecastYahoo Finance · Nov 13, 2026Update: US Equity Indexes Shrug Off Turmoil at Nvidia as CEO Jensen Huang ResignsYahoo Finance · Nov 12, 2026Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Nvidia Stock RecoversYahoo Finance · Nov 11, 2026Update: US Equity Indexes Drop as Inflation Data Strengthens Case for Fed Rate IncreaseYahoo Finance · Nov 10, 2026Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid October Consumer Inflation ReportYahoo Finance · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
20No pass
Philip Fisher
39No pass
Peter Lynch
32No pass
Joel Greenblatt
50No pass
Charlie Munger
20No pass
Terry Smith
19No pass
Questions about CDT Equity
Is CDT Equity a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CDT Equity AI analysis
What does CDT Equity do?
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. It is in Biotechnology.
Does CDT Equity pay a dividend?
No. CDT Equity does not pay a dividend at the moment; in 2025 it returned $106,000 to shareholders by buying back its own shares.
Is CDT Equity stock halal?
No. CDT Equity does not pass our halal screen: its debt is 190% of its market value, at or above the 33% limit. How we check
How has CDT Equity stock done over the past year?
Down 100.0% over the past twelve months, to $0.40. It traded between $0.40 and $14,437.50 and is 100.0% below its high.
Who are CDT Equity's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with CDT Equity's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.